Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP postoperative endoscopic recurrence study of rifaximin in Crohn's disease
NL-OMON46817Phase 2Completed
- Sponsor
- Alfasigma
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing Rifaximin-EIR with Placebo (2 arms). Primary endpoint: Endoscopic recurrence at week 26. Started Sep 2019; status: completed.
02
Drugs
rifaximin
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON46817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46817.